Icon

OMCAZIO (NDA220613)- (EQ 11.5MG BASE,EQ 23MG BASE,EQ 34.5MG BASE)

CABOZANTINIB LAURYLSULFATE HANDA ONCOL
EQ 11.5MG BASE,EQ 23MG BASE,EQ 34.5MG BASE
No Yes
2044-Jan-30 Expired
None None
None No
OMCAZIO is a kinase inhibitor indicated for the treatment of • patients with advanced renal cell carcinoma (RCC). • patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab. • patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. • adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 11.5MG BASE ** ** - - -
EQ 23MG BASE ** ** - - -
EQ 34.5MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.